跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要明确以临床试验中的治疗效应估计为目标,与因果推断相关,但具体因果识别条件未说明。

反馈分类问题

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者
Guoqing Diao
Donglin Zeng
Chunlei Ke
Haijun Ma
Qi Jiang
Joseph G Ibrahim

分量分别删失的复合终点半参数回归分析

研究问题
当复合临床终点的不同组成事件具有不同删失时间时,如何充分利用观测信息,估计治疗对无进展生存时间的影响?
方法与思路
作者提出似然方法,将终点拆分并联合建模无进展生存时间及进展至死亡的时间,同时区分各分量的删失时间。
材料陈述的贡献
摘要称该方法提供直接且改进的治疗效应估计,在所示模拟中优于若干替代方法并对多种错设稳健,另有前列腺癌试验应用。
阅读关注点
应核对各事件时间的联合模型、分量删失的假定与信息利用方式,以及治疗效应解释和错设稳健性覆盖的具体情形。
阅读边界
仅据版本未注明的 OpenAlex 索引摘要;摘要未说明因果识别、删失条件或稳健性的适用边界,不能认定任意错设下有效或推断刊本变化。

原文摘要

Composite endpoints with censored data are commonly used as study outcomes in clinical trials. For example, progression-free survival is a widely used composite endpoint, with disease progression and death as the two components. Progression-free survival time is often defined as the time from randomization to the earlier occurrence of disease progression or death from any cause. The censoring times of the two components could be different for patients not experiencing the endpoint event. Conventional approaches, such as taking the minimum of the censoring times of the two components as the censoring time for progression-free survival time, may suffer from efficiency loss and could produce biased estimates of the treatment effect. We propose a new likelihood-based approach that decomposes the endpoints and models both the progression-free survival time and the time from disease progression to death. The censoring times for different components are distinguished. The approach makes full use of available information and provides a direct and improved estimate of the treatment effect on progression-free survival time. Simulations demonstrate that the proposed method outperforms several other approaches and is robust against various model misspecifications. An application to a prostate cancer clinical trial is provided.

笔记与分组
相关领域论文